Myeloid Therapeutics, Inc., a US-based clinical stage mRNA-immunotherapy company, announced on Thursday that it has added Stanley Frankel, M.D., FACP and Brett Brett Kaplan, MD to its board of directors.
Dr Frankel has over 20 years of industry experience, including in the research, clinical development, and commercialisation of immuno-oncology and cellular therapies. He has held the position of corporate vice-president Immuno-Oncology at Celgene, senior vice-president, Global Drug Development for Cell Therapy at BMS, vice president, Clinical Development at Micromet, chief medical officer at Cytovia Therapeutics and a non-executive director at Precision Biosciences. He also serves on the Scientific Advisory Board at Sutro Biopharma, Immunai, and Minerva Biotechnologies. He is also an adjunct associate professor of Medicine at the Vagelos College of Physicians and Surgeons at Columbia University, New York.
Presently, Dr Kaplan serves as the chief financial and corporate development officer of Chroma Medicine Inc. He serves as audit committee chair and board member of Compass Therapeutics. He has served as the chief financial officer of Prevail Therapeutics, managing director at Evercore and in senior positions at Cubist and Lilly focused on corporate and business development.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval